Diabetes pharmacotherapy and effects on the musculoskeletal system
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Summary: Persons with type 1 or type 2 diabetes have a significantly higher fracture risk than age‐matched persons without diabetes, attributed to disease‐specific deficits in the microarchitecture and material properties of bone tissue. Therefore, independent effects of diabetes drugs on skeletal integrity are vitally important. Studies of incretin‐based therapies have shown divergent effects of different agents on fracture risk, including detrimental, beneficial, and neutral effects. The sulfonylurea class of drugs, owing to its hypoglycemic potential, is thought to amplify the risk of fall‐related fractures, particularly in the elderly. Other agents such as the biguanides may, in fact, be osteo‐anabolic. In contrast, despite similarly expected anabolic properties of insulin, data suggests that insulin pharmacotherapy itself, particularly in type 2 diabetes, may be a risk factor for fracture, negatively associated with determinants of bone quality and bone strength. Finally, sodium‐dependent glucose co‐transporter 2 inhibitors have been associated with an increased risk of atypical fractures in select populations, and possibly with an increase in lower extremity amputation with specific SGLT2I drugs. The role of skeletal muscle, as a potential mediator and determinant of bone quality, is also a relevant area of exploration. Currently, data regarding the impact of glucose lowering medications on diabetes‐related muscle atrophy is more limited, although preclinical studies suggest that various hypoglycemic agents may have either aggravating (sulfonylureas, glinides) or repairing (thiazolidinediones, biguanides, incretins) effects on skeletal muscle atrophy, thereby influencing bone quality. Hence, the therapeutic efficacy of each hypoglycemic agent must also be evaluated in light of its impact, alone or in combination, on musculoskeletal health, when determining an individualized treatment approach. Moreover, the effect of newer medications (potentially seeking expanded clinical indication into the pediatric age range) on the growing skeleton is largely unknown. Herein, we review the available literature regarding effects of diabetes pharmacotherapy, by drug class and/or by clinical indication, on the musculoskeletal health of persons with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism
Ferron, M., Wei, J., Yoshizawa, T., Del Fattore, A., DePinho, R. A., Teti, A., Ducy, P., & Karsenty, G. (2010) · Cell · doi:10.1016/j.cell.2010.06.003 · Cited by 1,123 · cited 1×
“results in impaired bone formation, abnormal trabecular architecture, smaller cortices, and increased fragility, dependent on the developmental stage in which the insulin receptor was eliminated and in a sex‐specific manner.(56,77,78) In other studies, exogenous insulin administration shows a dose‐dependent ability to…”
BackgroundMetformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778 · cited 25×
“In humans with T2D, greater muscle mass due to larger body size may exist, compared with healthy adults; however, their muscle performance is negatively affected.457 Also, with age, muscle wasting in patients withT2D is evident.431 In certain animal models of T2D, such as the db/db mice, decreased exercise capacity an…”
BackgroundInfluentialDecreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., & Newman, A. B. (2006) · Diabetes · doi:10.2337/db05-1183 · Cited by 751 · cited 1×
“In humans with T2D, greater muscle mass due to larger body size may exist, compared with healthy adults; however, their muscle performance is negatively affected.(457) Also, with age, muscle wasting in patients withT2D is evident.”
BackgroundMaruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 3×
“7% of subjects experienced a bone fracture, compared with no fractures in the placebo group.(382) In contrast, by cumulative meta‐ analyses of randomized controlled trials, along with systematic literature review, several later publications have subsequently demonstrated that the incidence of skeletal fracture, compar…”
BackgroundResultInfluentialBennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Wang, X., Hu, Z., Hu, J., Du, J., & Mitch, W. E. (2006) · Endocrinology · doi:10.1210/en.2006-0251 · Cited by 600
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
State of the art paper Sulfonylureas and their use in clinical practice
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.53304 · Cited by 514
Sulfonylurea Stimulation of Insulin Secretion
Proks, P., Reimann, F., Green, N., Gribble, F., & Ashcroft, F. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s368 · Cited by 510
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1712572 · Cited by 415
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356
Pedersen, M., Bruunsgaard, H., Weis, N., Hendel, H. W., Andreassen, B. U., Eldrup, E., Dela, F., & Pedersen, B. K. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(03)00027-7 · Cited by 342
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253 · cited 3×
“Additionally, saxagliptin (as monotherapy or add‐on therapy), in recent data from pooled analysis of 20 randomized control studies demonstrated a higher incidence of fracture with saxagliptin,301 a risk which was not, however, reported in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabet…”
BackgroundInfluentialStructure of a Pancreatic ATP-Sensitive Potassium Channel
Li, N., Wu, J.-X., Ding, D., Cheng, J., Gao, N., & Chen, L. (2017) · Cell · doi:10.1016/j.cell.2016.12.028 · Cited by 252
Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients.
Nair, K. S., Ford, G. C., Ekberg, K., Fernqvist-Forbes, E., & Wahren, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118000 · Cited by 239
Abdulla, H., Smith, K., Atherton, P. J., & Idris, I. (2016) · Diabetologia · doi:10.1007/s00125-015-3751-0 · Cited by 229
Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth
Vehik, K., Hamman, R. F., Lezotte, D., Norris, J. M., Klingensmith, G., Bloch, C., Rewers, M., & Dabelea, D. (2007) · Diabetes Care · doi:10.2337/dc06-1837 · Cited by 226
Advanced glycation end products, diabetes, and bone strength
Yamamoto, M., & Sugimoto, T. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0332-1 · Cited by 215
Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo
Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200312135 · Cited by 206 · cited 1×
“As would be consistent with these anti‐resorption effects, mice with targeted deletion of the amylin gene exhibit low bone mass, attributable to chronically unrestricted bone resorption.(421,422) Additionally, daily amylin treatment has been shown to inhibit ovariectomy‐induced trabecular bone loss in rats, again by i…”
BackgroundMa, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200 · cited 1×
“Induction of RUNX2, alkaline phosphatase, and collagen 1 expression as well as increased P1NP, alkaline phosphatase, and osteocalcin serum levels (indicative of bone formation) have been reported with treatment with a GLP‐1R agonist in ovariectomized rats.(324) Both exenatide and liraglutide are associated with increa…”
BackgroundTsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198 · cited 1×
“affecting calcium deposition in bone.(281) Furthermore, GIP has been shown to inhibit the activity of mature osteoclasts.”
BackgroundChai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194
Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193 · cited 2×
“Specifically, a recent, two‐center, randomized, parallel‐group clinical trial compared the effects of exenatide on BMD and bone turnover markers to insulin or pioglitazone treatment (n = 62 newly diagnosed T2D patients) and did not find any improvement in either BMD or bone biomarkers after 24 weeks of treatment despi…”
BackgroundInfluentialMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Blau, J. E., Bauman, V., Conway, E. M., Piaggi, P., Walter, M. F., Wright, E. C., Bernstein, S., Courville, A. B., Collins, M. T., Rother, K. I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99123 · Cited by 172
Insulin sensitizers may attenuate lean mass loss in older men with diabetes
Lee, C. G., Boyko, E. J., Barrett-Connor, E., Miljkovic, I., Hoffman, A. R., Everson-Rose, S. A., Lewis, C. E., Cawthon, P. M., Strotmeyer, E. S., Orwoll, E. S., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1032 · Cited by 168
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166 · cited 1×
“However, no change in bone formation markers (bone‐specific alkaline phosphatase, osteocalcin, P1NP) or in urine N‐telopeptides was observed.(378) In contrast, in adults with T2D inadequately controlled on metformin, dapagliflozin treatment (10 mg, once daily; NCT 00855166), whether analyzed at ~1(379) or 2 years(337)…”
BackgroundKim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Pereira, M., Jeyabalan, J., Jørgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., Chavassieux, P., Orriss, I. R., Cleasby, M. E., & Chenu, C. (2015) · Bone · doi:10.1016/j.bone.2015.08.006 · Cited by 137
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Chow, L. S., Albright, R. C., Bigelow, M. L., Toffolo, G., Cobelli, C., & Nair, K. S. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00003.2006 · Cited by 127
Amylin Stimulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice
Cornish, J., Callon, K. E., Cooper, G. J. S., & Reid, I. R. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1163 · Cited by 126
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 24×
“In humans with T2D, greater muscle mass due to larger body size may exist, compared with healthy adults; however, their muscle performance is negatively affected.457 Also, with age, muscle wasting in patients withT2D is evident.431 In certain animal models of T2D, such as the db/db mice, decreased exercise capacity an…”
BackgroundInfluentialIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121 · cited 3×
“4 hours) than GLP‐1 due to a difference in the second amino acid, which makes it resistant to degradation by DPP‐4, without losing its biologic activity.(275) Exenatide was approved by the US FDA in April of 2005 for treatment of T2D.”
BackgroundDo sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit
Datta, H. K., Zaidi, M., Wimalawansa, S. J., Ghatei, M. A., Beacham, J. L., Bloom, S. R., & MacIntyre, I. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92391-7 · Cited by 114 · cited 1×
“At the same time, amylin inhibits osteoclastic bone resorption and/or lowers plasma calcium as demonstrated in mice, rats, and rabbits.(417,418) In rats specifically, an amylin‐induced decrease in osteoclast surface (OcS/BS) and erosion surface (ES/BS) has been illustrated by dynamic histomorphometry.”
BackgroundNaznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
Nyman, J. S., Even, J. L., Jo, C.-H., Herbert, E. G., Murry, M. R., Cockrell, G. E., Wahl, E. C., Bunn, R. C., Lumpkin, C. K., Fowlkes, J. L., et al. (2011) · Bone · doi:10.1016/j.bone.2010.12.016 · Cited by 112 · cited 1×
“tion has occurred and circulating insulin levels are very low to undetectable, skeletal micro‐architecture, bone quality, and fracture resistance are compromised, and fracture healing and skeletal regeneration are impaired.(53,68) These skeletal deficits are in large part due to decreased bone formation and significan…”
BackgroundSelf-citationLu, N., Sun, H., Yu, J., Wang, X., Liu, D., Zhao, L., Sun, L., Zhao, H., Tao, B., & Liu, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132744 · Cited by 108 · cited 1×
“Both exenatide and liraglutide are associated with increases in bone mass, in both trabecular(313,324-326) and cortical bone.(325,326) Additionally, CTX levels have been shown to decrease with GLP‐1 analogue treatment in aged ovariectomized rats,(324) and”
BackgroundOstler, J. E., Maurya, S. K., Dials, J., Roof, S. R., Devor, S. T., Ziolo, M. T., & Periasamy, M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00277.2013 · Cited by 102 · cited 1×
“have been observed; however, other models of T2D, such as the TallyHo mice, do not exhibit muscle atrophy and loss of muscle function.(458) This indicates that additional factors to hyperglycemia and insulin resistance are necessary for muscle loss in T2D.”
MethodCornish, J., Callon, K. E., King, A. R., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.4.e694 · Cited by 102
Zhang, Y. S., Weng, W. Y., Xie, B. C., Meng, Y., Hao, Y. H., Liang, Y. M., & Zhou, Z. K. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4649-8 · Cited by 93 · cited 2×
“This contrasts the findings by Zhang et al, who performed a meta‐analysis including 57 clinical trials involving 49 602 participants of whom 28 353 were treated with exenatide, liraglutide, semaglutide, dulaglutide, albiglutide, or lixisenatide.(331) Comparators included GLP‐1R agonists, other hypoglycemic drugs, or p…”
BackgroundMethodWu, X., Li, S., Xue, P., & Li, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.018 · Cited by 92 · cited 1×
“In vitro studies have demonstrated that GLP‐1 analogues lead to an increase of RUNX2,(317) alkaline phosphatase,(317) collagen‐1,(317) and osteocalcin expression in MC3T3 cells,(278,317) and most studies support that they promote proliferation and differentiation of these cells.(317,318) Liraglutide has also been show…”
Glucose Transporter-4 Facilitates Insulin-Stimulated Glucose Uptake in Osteoblasts
Li, Z., Frey, J. L., Wong, G. W., Faugere, M.-C., Wolfgang, M. J., Kim, J. K., Riddle, R. C., & Clemens, T. L. (2016) · Endocrinology · doi:10.1210/en.2016-1583 · Cited by 86
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85 · cited 1×
“Based on the ACCORD Bone study, follow‐up of female patients who had discontinued TZDs showed that fracture risk is reduced within 1 to 2 years of discontinuation.(227) The increased fracture risk observed in patients with T2D treated with TZDs is likely multifactorial, and both the deleterious effects of diabetes on…”
MethodDriessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79
Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw182 · Cited by 78
Amylin‐amide: a new bone‐conserving peptide from the pancreas
Zaidi, M., Datta, H., Bevis, P., Wimalawansa, S., & MacIntyre, I. (1990) · Experimental Physiology · doi:10.1113/expphysiol.1990.sp003429 · Cited by 61
Amin, N. B., Wang, X., Mitchell, J. R., Lee, D. S., Nucci, G., & Rusnak, J. M. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12486 · Cited by 60
Mele, A., Calzolaro, S., Cannone, G., Cetrone, M., Conte, D., & Tricarico, D. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.28 · Cited by 58
Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk
Malin, S. K., & Braun, B. (2016) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000070 · Cited by 56
Dissociation of the effects of amylin on osteoblast proliferation and bone resorption
Cornish, J., Callon, K. E., Lin, C. Q.-X., Xiao, C. L., Mulvey, T. B., Coy, D. H., Cooper, G. J. S., & Reid, I. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.5.e827 · Cited by 54
Chai, W., Fu, Z., Aylor, K. W., Barrett, E. J., & Liu, Z. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00205.2016 · Cited by 51
Shea, M. K., Nicklas, B. J., Marsh, A. P., Houston, D. K., Miller, G. D., Isom, S., Miller, M. E., Carr, J. J., Lyles, M. F., Harris, T. B., et al. (2011) · Obesity · doi:10.1038/oby.2010.327 · Cited by 49 · cited 1×
“However, pioglitazone did not prevent skeletal muscle loss when compared with resistance training in a group of older, non‐ diabetic overweight, or obese subjects enrolled in a hypocaloric weight‐loss program.(485) Evaluation of the transcriptome of skeletal muscle of subjects with impaired glucose tolerance on piogli…”
BackgroundBone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0793 · Cited by 43 · cited 1×
“Grey et al found that pioglitazone when compared with control was associated with increased bone loss at the femur but no other sites.(217) Finally, a recent meta‐analysis on the effects of TZDs on bone reported decreases in BMD at the lumbar spine, total hip, and forearm.”
BackgroundAmylin inhibits ovariectomy-induced bone loss in rats
Horcajada-Molteni, M., Davicco, M., Lebecque, P., Coxam, V, Young, A., & Barlet, J. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650663 · Cited by 40 · cited 1×
“Additionally, daily amylin treatment has been shown to inhibit ovariectomy‐induced trabecular bone loss in rats, again by inhibiting bone resorption.(423)”
BackgroundGilbey, S. G., Ghatei, M. A., Bretherton-Watt, D., Zaidi, M., Jones, P. M., Perera, T., Beacham, J., Girgis, S., & Bloom, S. R. (1991) · Clinical Science · doi:10.1042/cs0810803 · Cited by 39
Systemic administration of a novel octapeptide, amylin-(1—8), increases bone volume in male mice
Cornish, J., Callon, K. E., Gasser, J. A., Bava, U., Gardiner, E. M., Coy, D. H., Cooper, G. J. S., & Reid, I. R. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.4.e730 · Cited by 38
Pietschmann, P., Farsoudi, K. H., Hoffmann, O., Klaushofer, K., Hörandner, H., & Peterlik, M. (1993) · Bone · doi:10.1016/8756-3282(93)90244-5 · Cited by 28
Nyomba, B. L., Freymond, D., Raz, I., Stone, K., Mott, D. M., & Bogardus, C. (1990) · Metabolism · doi:10.1016/0026-0495(90)90096-u · Cited by 17
Cited by
Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
Hong, Y., Lee, J. H., Jeong, K. W., Choi, C. S., & Jun, H. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12434 · Cited by 188
Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis
Zhang, Y.-S., Zheng, Y.-D., Yuan, Y., Chen, S.-C., & Xie, B.-C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735824 · Cited by 117
GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101
The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N. (2022) · Medicina · doi:10.3390/medicina58020224 · Cited by 74
“The difference in doses and duration of therapy with GLP1RAs and the difference in the number of trials included in meta-analyses may have led to the above-mentioned conflicting findings [27].”
BackgroundResult
Metadata
- Authors
- Kalaitzoglou, E., Fowlkes, J. L., Popescu, I., & Thrailkill, K. M.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2018-12-20
- Volume
- 35
- Issue
- 2
- Pages
- e3100-e3100
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2901779257
- Cited by
- 100
- References
- 78
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.